Background
==========

Major histocompatibility complex (MHC) class I molecules, HLA-A, -B, and -C, are cell surface glycoproteins consisting of a polymorphic heavy α chain non-covalently linked to a light chain, β~2~-microglobulin (β~2~m). HLA-A and -B molecules play critical roles in cell mediated immune responses by binding short antigenic peptide fragments and presenting them on the surface of antigen-presenting cells for recognition by the CD8^+^cytotoxic T lymphocyte (CTL). Although several HLA-C specificities with CTL epitopes have been reported \[[@B1],[@B2]\], much remains unknown with regards to their role in the immune response against viral antigens in part due to their poor expression at the cell surface \[[@B3],[@B4]\]. Recent research shows that this group of molecules plays a major role in the control of human immunodeficiency virus type 1 (HIV-1) infection \[[@B5]\]. Improved understanding of peptide binding to this group of molecules is important in the study of HIV-1 disease progression, as well as the design of effective HIV peptide vaccines.

The HLA-C allele, Cw\*0401, is of particular interest in the study of HIV-1 disease progression because it is the restriction element for HIV-1 proteins \[[@B5]\]. Two HIV-1 proteins (p24^gag^and gp160^gag^) are currently known to be restricted by Cw\*0401 \[[@B5]\]. Cw\*0401 is present in approximately 10% of the general population \[[@B6]\]. The allele is expressed intracellularly in amounts comparable with HLA-A and -B molecules, but is poorly expressed at the cell surface \[[@B7],[@B8]\]. Improved understanding of peptide binding to this molecule is important for elucidating its role in HIV-1 disease progression.

Computational strategies for prediction of peptide binding to HLA-A and -B molecules are relatively advanced \[[@B9]\], while sequence-based predictive models for HLA-C molecules have encountered limited success due to the lack of experimental training data \[[@B10]\]. Two matrix-based prediction algorithms for Cw\*0401 were reported \[[@B11],[@B12]\], but a sequence independent approach is still lacking. To overcome these limitations, we have developed a structure-based predictive technique that integrates the strength of Monte Carlo simulations and homology modeling \[[@B13]-[@B15]\]. This method utilizes a probe or \"base fragment\" to sample different regions of the receptor binding site, followed by loop closure and refinement of the entire class I peptide. The technique has been successfully applied to analyze peptides binding to a variety of MHC class II alleles \[[@B14],[@B15]\]. In this work, we now extend our analysis to peptides presented by the class I HLA-C molecule. We investigated the HIV-1 p24^gag^and gp160^gag^peptide binding repertoire of Cw\*0401 and illustrate that areas with high concentration of T-cell epitopes or \"immunological hot spots\" are potentially well distributed throughout both HIV-1 p24^gag^and gp160^gag^. We also show that Cw\*0401 can possibly bind antigenic peptides in amounts comparable to both HLA-A and -B molecules. Characterization of predicted Cw\*0401 binding sequences reveal that Cw\*0401 may bind a large variety of amino acids at anchor positions with common physico-chemical properties which correlate well with existing experimental studies \[[@B11]\].

Results and discussion
======================

Cw\*0401 predictive model
-------------------------

High predictivity (*r*^2^= 0.88, *s*= 3.56 kJ/mol, q^2^= 0.84, s~press~= 5.18 kJ/mol) is achieved when tested on the training dataset of 6 Cw\*0401 peptide sequences. The Cw\*0401 predictive model outperforms the predictive models done by Rognan *et al*. \[[@B16]\] on training datasets of 5 A\*0204 (*r*^2^= 0.85, *s*~*press*~= 2.40 kJ/mol) and 37 2K^k^(*r*^2^= 0.78, *s*~*press*~= 3.16 kJ/mol) peptide sequences and is comparable with our previous DRB1\*0402 (r^2^= 0.90, s = 1.20 kJ/mol, q^2^= 0.82, s~press~= 1.61 kJ/mol) and DQB1\*0503 (r^2^= 0.95, s = 1.20 kJ/mol, q^2^= 0.75, s~press~= 2.15 kJ/mol) prediction models on a training set of 8 peptides \[[@B17]\]. The cross-validation coefficient *q*^2^and the standard error of prediction *s*~*press*~are stable, with *q*^2^= 0.84 and *s*~*press*~= 5.18 kJ/mol. This iterative regression procedure validates the internal consistency of the scoring function in the current model, rendering it suitable for predictions on the test dataset obtained from biochemical studies. The predictive performance of our model is further validated using the test dataset of 58 peptides. The external validation results indicate that our Cw\*0401 predictive model is suitable for discriminating binding ligands from the background with high accuracy (A~ROC~= 0.93) with sensitivity of 76% (SP = 0.95).

Characterization of Cw\*0401 binding peptides
---------------------------------------------

An in-depth analysis was performed to investigate the characteristics of Cw\*0401 binding peptides. A panel of 2279 sequences was generated using an overlapping sliding window of size 9 across the entire p24^gag^\[[@B5]\] and gp160^gag^\[[@B18]\] glycoproteins and modeled into the binding groove of Cw\*0401. From these sequences, a total of 877 binding sequences (predicted binders; SE = 76%, SP = 80%) were selected and a systematic analysis was performed to analyze the number of occurrence of individual amino acid residues and physico-chemical properties \[[@B19]\] at each position of Cw\*0401 binding peptides.

Peptide position p2 is characterized by alanine (10%), glycine (13%), leucine (9%), serine (9%). 60% of the predicted residues at this position are hydrophobic in nature, while 93% are neutral. These properties correlate with the physico-chemical properties of existing binding motif (Tyr/Phe) at p2 \[[@B11]\] as well as with the observed conservation in the test data (Table [1](#T1){ref-type="table"}: Phe -- 58% and Tyr -- 26%). The p3 position shows a strong preference for glycine (11%) and threonine (8%). Existing anchor residues at this position are aspartic acid and histidine, which accounts for 9% of the total position-specific composition in the dataset. The p4 position shares similar characteristics as p3 (glycine: 9%; threonine: 8%), with additional preference for leucine (8%). Similar results were obtained at the p5 position (alanine: 8%; glycine: 9%; leucine: 8%). At p6, characteristic residues include glycine (9%) and leucine (8%). This position is favored by neutral (81%) acyclic (89%), medium/large (77%), and hydrophobic (51%) residues. The physico-chemical properties of these residues are in agreement with Val/Ile/Leu as reported in earlier studies \[[@B11]\] and is comparable with the conservation in the test dataset reported in Table [1](#T1){ref-type="table"} (Val -- 29%, Ile -- 12%, Leu and Pro -- 10%). Finally, the p9 position was defined by six amino acids, including alanine (8%), glycine (10%), isoleucine (8%), leucine (8%), threonine (9%), and valine (8%). This position is primarily dominated by neutral (90%) and hydrophobic (58%) residues, and agrees with profiles of Leu/Phe as previously reported \[[@B11]\] and is consistent with the conservation in the test dataset reported in Table [1](#T1){ref-type="table"} (Leu and Phe -- 39%,). Collectively, our data indicates that individual binding pockets may not be highly specific as previously reported \[[@B11]\] but can rather accommodate a wide-range of anchor residues with common physico-chemical properties. We attribute the discrepancies to two possibilities: i) the lack of extensive research on Cw\*0401 peptides; and ii) natural peptides carrying these residues may be present in small amount and were thus not detected by experimental studies.

###### 

HLA-Cw4 dataset used in this study.

  **No.**   **Category**   **Source**                                                                      **Peptide**   **IC~50~(nM)**   **Ref.**
  --------- -------------- ------------------------------------------------------------------------------- ------------- ---------------- ----------
  1         Training Set   Cw3 consensus                                                                   FAMPNFQTL     651              24
  2         Training Set   Cw6 consensus                                                                   IPFPIVRYL     \>30000          24
  3         Training Set   Cw7 consensus                                                                   KYPDFVDAL     2.4              24
  4         Training Set   Cw4 consensus                                                                   QYDDAVYKL     18               24
  5         Training Set   Histone H3.3                                                                    RYRPGTVAL     \>30000          24
  6         Training Set   Unknown Cw6 natural ligand                                                      YQFTGIKKY     \>30000          24
  7         Test Set       Transcripton factor SUPT4H 56--64                                               SFDGIIAMM     Binder           10
  8         Test Set       Transducin-like 3 120--128                                                      AFDPTSTLL     Binder           10
  9         Test Set       UBE3B variant 1 742--750                                                        VFDPALNLF     Binder           10
  10        Test Set       XP_173235 3--11                                                                 LFDITGQDF     Binder           10
  11        Test Set       8 59--67                                                                        VYDTNPAKF     Binder           10
  12        Test Set       Acyl-CoA synthetase 4 82--90                                                    LFDHAVSKF     Binder           10
  13        Test Set       Adenosylhomocyteinehydrolase 566--574                                           SFDAHLTEL     Binder           10
  14        Test Set       ART-1 Adenocarcinoma antigen 21--29                                             SFDLLPREF     Binder           10
  15        Test Set       ATP-binding cassette, sub-family F, member 3 500--508                           YYDPKHVIF     Binder           10
  16        Test Set       Block of proliferation 1 639--647                                               SYDSKLVWF     Binder           10
  17        Test Set       BM-015 144--152                                                                 HFDPEVVQI     Binder           10
  18        Test Set       CDC45 541--549                                                                  HFDLSVIEL     Binder           10
  19        Test Set       Cholesterol acyltransferase 72--80                                              HFDDFVTNL     Binder           10
  20        Test Set       Chromosome 20 open reading frame 40 318--326                                    FFDNISSEL     Binder           10
  21        Test Set       Elongation factor 2 265--273                                                    YFDPANGKF     Binder           10
  22        Test Set       Epithelial cell transforming oncogene 21--29                                    IFDSKVTEI     Binder           10
  23        Test Set       Ethanolamine kinase EKI1 132--141                                               HWDPQEVTL     Binder           10
  24        Test Set       Eukaryotic translation initiation factor 3, Su 6 interacting protein 478--486   FLDLTEGEF     Binder           10
  25        Test Set       Fatty acid synthetase 544--552                                                  TFDDIVHSF     Binder           10
  26        Test Set       FK506 binding protein 9 303--311                                                VFDIHVIDF     Binder           10
  27        Test Set       Glutamine:fructose-6-phosphate amidotransferase (GFAT) 345--353                 NFDDYTVNL     Binder           10
  28        Test Set       Tousled-like kinase 456--464                                                    AFDLTEQRY     Binder           10
  29        Test Set       Transcription factor IIE 144--152                                               LFDPMTGTF     Binder           10
  30        Test Set       HSP 70 kDa 1A 179--205                                                          IFDLGGGTF     Binder           10
  31        Test Set       HSPC198 19--27                                                                  SYDLFVNSF     Binder           10
  32        Test Set       HSP J2 156--164                                                                 SFDTGFTSF     Binder           10
  33        Test Set       Hypothetical protein FLJ00365 80--88                                            YFDAIPVTM     Binder           10
  34        Test Set       Hypothetical protein FLJ11220 373--381                                          YLPDFLDYF     Binder           10
  35        Test Set       Hypothetical protein FLJ20343 415--423                                          RFDEAYIYM     Binder           10
  36        Test Set       Insuline degrading enzyme IDE 150--158                                          YFDVSHEHL     Binder           10
  37        Test Set       Integrin alpha-V (Vitronectin) 224--232                                         KYDPNVYSI     Binder           10
  38        Test Set       KCIP-1 186--194                                                                 AFDEAIAEL     Binder           10
  39        Test Set       KIAA0461 721--729                                                               SMDPLPVFL     Binder           10
  40        Test Set       KIAA1463 444--452                                                               FYDERIVVV     Binder           10
  41        Test Set       KIAA1921 350--358                                                               VYDGKIYTL     Binder           10
  42        Test Set       Metalloproteinase 10 331--339                                                   FWPSLPSYL     Binder           10
  43        Test Set       Methionine-tRNA synthetase 2 (mitochondrial) 58--66                             YYDEKVVKL     Binder           10
  44        Test Set       Mucin-5B 168--176                                                               TFDGTSYTF     Binder           10
  45        Test Set       Myosin phosphatase target subunit 1 37--45                                      KFDDGAVFL     Binder           10
  46        Test Set       Nuclear autoantigenic sperm protein 599--607                                    QYDEAVAQF     Binder           10
  47        Test Set       Nucleoporin NUP358 261--269                                                     SFDSALQSV     Binder           10
  48        Test Set       P621 70--78                                                                     VFDKTLAEL     Binder           10
  49        Test Set       Phosphate carrier precursor 331--339                                            IYDSVKVYF     Binder           10
  50        Test Set       PRO2242 61--69                                                                  YFDPQYFEF     Binder           10
  51        Test Set       Protein phosphatase 6 102--110                                                  KWPDRITLL     Binder           10
  52        Test Set       Putative prostate tumor suppressor 165--173                                     TFDLQRIGF     Binder           10
  53        Test Set       Rac1 168--176                                                                   VFDEAIRAV     Binder           10
  54        Test Set       RNA Helicase A 697--705                                                         VFDPVPVGV     Binder           10
  55        Test Set       Similiar to KIAA1911 80--88                                                     FWDGKIVLV     Binder           10
  56        Test Set       Topoisomerase I 241--249                                                        YYDGKVMKL     Binder           10
  57        Test Set       Tensin 3 143--151                                                               FYDDKVSAL     Binder           10
  58        Test Set       HIV-1 (BRU) gp120 350--358                                                      SFNCGGEFF     Binder           18
  59        Test Set       HIV-1 (BRU) gag p24 307--315                                                    QASQEVKNW     Binder           21
  60        Test Set       Synthetic peptide                                                               AYDDAVYKL     Binder           25
  61        Test Set       Cw7 consensus                                                                   AYADFVYAY     \>30000          24
  62        Test Set       CKShs2                                                                          KYFDEHYEY     \>30000          24
  63        Test Set       Unknown Cw6 natural ligand                                                      YRHDGGNVL     \>30000          24
  64        Test Set       Unknown Cw7 natural ligand                                                      NKADVILKY     \>30000          24

Prediction of p24^gag^and gp160^gag^immunological hot spots
-----------------------------------------------------------

The potential T-cell epitope repertoire (data not shown) and immunological hot spots (Figure [1](#F1){ref-type="fig"}) for HIV-1 p24^gag^and gp160^gag^are well distributed throughout both glycoproteins. The known p24^gag^epitope (p24 168--175) and gp160^gag^epitope (gp160 375--383) were successfully predicted by our model at the threshold of -200 (SE = 76%, SP = 80%) \[[@B5],[@B20]\]. At this threshold, the number of predicted hot spots for p24^gag^are fourteen (p24 20--75, 89--148, 143--262, 311--381, 447--506, 526--590, 664--727, 708--791, 873--930, 996--1053, 1054--1157, 1157--1316, 1308--1368, and 1378--1427), with an estimated FN = 3, and FP = 3 for SE = 0.76 and SP = 0.95 (Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}). For gp160^gag^we predict nine hot spots (gp160 44--89, 102--171, 174--289, 341--504, 489--559, 581--639, 667--721, 708--766, and 793--852), with an estimated FN = 2, FP = 2 for SE = 0.76 and SP = 0.95 (Figure [1](#F1){ref-type="fig"} and Table [3](#T3){ref-type="table"}). The results presented here indicate that Cw\*0401 can bind antigenic peptides with specificities comparable to HLA-A and -B molecules, and any variability in antigen expression may be directly related to the loss or reduced cell surface expression of the molecule by mechanisms as yet unknown \[[@B8],[@B21]\].

###### 

Predicted Cw\*0401-specific immunological hotspots for p24^gag^.

  ----------------------------------------------------------------------------
  No.   Position     Sequence
  ----- ------------ ---------------------------------------------------------
  1     20--75       RLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQTGSE\
                     EL

  2     89--148      YNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNY\
                     PIVQNIQGQMVHQAIS

  3     143--262     PIVQNIQGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNT\
                     MLNTVGGHQAAMQMLKETINEEAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTT\
                     STLQEQIGWMTNNPPIPVGEIY

  4     311--381     QEVKNWMTETLLVQNANPDCKTILKALGPAATLEEMMTACQGVGGPGHKARVLA\
                     EAMSQVTNSATIMMQRG

  5     447--506     EFSSEQTRANSPTRRELQVWGRDNNSPSEAGADRQGTVSFNFPQVTLWQRPLVT\
                     IKIGGQ

  6     526--590     LPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLT\
                     QIGCTLNFPIS

  7     664--727     FRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPLDEDFRKYTAF\
                     TIPSINNETP

  8     708--791     DEDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQ\
                     NPDIVIYQYMDDLYVGSDLEIGQHRTKIEE

  9     873--930     TKALTEVIPLTEEAELELAENREILKEPVHGVYYDPSKDLIAEIQKQGQGQWTY\
                     QIYQ

  10    996--1053    TWIPEWEFVNTPPLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTNRG\
                     RQKV

  11    1054--1157   VTLTDTTNQKTELQAIYLALQDSGLEVNIVTDSQYALGIIQAQPDQSESELVNQ\
                     IIEQLIKKEKVYLAWVPAHKGIGGNEQVDKLVSAGIRKVLFLDGIDKAQDE

  12    1157--1316   DEHEKYHSNWRAMASDFNLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQL\
                     DCTHLEGKVILVAVHVASGYIEAEVIPAETGQETAYFLLKLAGRWPVKTIHTDN\
                     GSNFTGATVRAACWWAGIKQEFGIPYNPQSQGVVESMNKELKKIIGQVRDQA

  13    1308--1368   IIGQVRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQ\
                     KQITKIQ

  14    1378--1427   RNPLWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDC
  ----------------------------------------------------------------------------

###### 

Predicted Cw\*0401-specific immunological hotspots for gp160^gag^.

  ------------------------------------------------------------------------
  No.   Position   Sequence
  ----- ---------- -------------------------------------------------------
  1     44--89     VWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNV

  2     102--171   EQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLGNATNTNSSNTNSSSGEMM\
                   MEKGEIKNCSFNISTSIR

  3     174--289   VQKEYAFFYKLDIIPIDNDTTSYTLTSCNTSVITQACPKVSFEPIPIHYCAP\
                   AGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVI\
                   RSANFTDNAKTI

  4     341--504   AKWNATLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNS\
                   TQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRIKQFINMWQEVGKAMYAPPI\
                   SGQIRCSSNITGLLLTRDGGNNNNGSEIFRPGGGDMRDNWRSELYKYKVVKI\
                   EPLGVAPT

  5     489--559   KYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGARSMT\
                   LTVQARQLLSGIVQQQNN

  6     581--639   LQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNNMT\
                   WMEWDRE

  7     667--721   ELDKWASLWNWFNITNWLWYIKIFIMIVGGLVGLRIVFAVLSIVNRVRQGYS\
                   PLS

  8     708--766   SIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLA\
                   LIWDDLR

  9     793--852   RGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRA\
                   IRHIPRRI
  ------------------------------------------------------------------------

![Predicted start positions of Cw\*0401-specific hotspots (sliding window size = 30) along (A) p24^gag^and (B) gp160^gag^glycoproteins. Scores are computed based on the sum of predicted binding energies of top four binders within the 30 amino acid sliding window. Predicted hotspots regions are shown in blue boxes with experimentally verified regions shown in red.](1745-7580-3-7-1){#F1}

Conclusion
==========

Due to the low expression of HLA-C molecules at the cell surface, their role in cell mediated immune responses remain poorly understood. Collectively, the outcome of this analysis provides insights into the binding specificities of Cw\*0401. Our data strongly indicate that Cw\*0401 can bind antigenic peptides in amounts comparable to both HLA-A and -B molecules, and show the existence of a potentially large number of Cw\*0401-specific T-cell epitopes that are evenly distributed throughout both HIV-1 p24^gag^and gp160^gag^glycoproteins. It remains to be determined what proportion of these peptides may be expressed at the cell surface and capable of eliciting functional responses. Probably, pre-selection of candidate HLA-C peptides may occur at the TAP level, prior to peptide loading in the ER \[[@B8]\]. Consequently, a higher concentration of peptides is necessary for complexation with HLA-C molecules, resulting in their release from TAP. This provides a possible explanation for the reduced cell surface expression of HLA-C molecules \[[@B8]\].

Methods
=======

Data
----

### Crystallographic data

The coordinates of Cw\*0401 were obtained from the Protein Databank (PDB) with PDB code 1QQD \[[@B22]\]. The structure was relaxed by conjugate gradient minimization, using the Internal Coordinate Mechanics (ICM) software \[[@B23]\].

### Experimental binding data

The dataset comprises a total of 64 (57 binders and 7 non-binders) 9-mer peptides (Table [1](#T1){ref-type="table"}). The available dataset is divided into training and testing datasets. Peptides with experimental IC~50~values were selected as training data for optimizing the empirical free energy function (refer *Empirical Free Energy Function*). Due to the lack of experimental data, only 9 peptides with experimental IC~50~values were identified, six (three binders and three non-binders) of which were used for training, while the remainder (four non-binders) were included in the test dataset as true negatives. Therefore, the training dataset contained six peptides with experimentally determined IC~50~values (2 high-affinity binders, 1 medium-affinity binder, and 3 non-binders) derived from biochemical studies \[[@B24]\], while the testing dataset comprised the remainder 58 peptides (54 binders and 4 non-binders) \[[@B10],[@B18],[@B21],[@B24],[@B25]\]. Experimental IC~50~values were classified as follows -- high-affinity binders: IC~50~≤ 500 nM, medium-affinity binders: 500 nM \< IC~50~≤ 1500 nM, low-affinity binders: 1500 \< IC~50~≤ 5000 nM and non-binders: 5000 \< IC~50~.

### HIV-1 sequence data

The sequences of HIV-1 p24^gag^and gp160^gag^glycoproteins were obtained from UniProt \[[@B26]\]. The accession numbers for p24^gag^and gp160^gag^glycoproteins used in this study are P04585 and P03377 respectively.

Model
-----

### Peptide docking

Docking was performed according to the procedure utilized in previous similar works \[[@B13]-[@B15]\]: (i) pseudo-Brownian rigid body docking of peptide fragments to the ends of the binding groove, (ii) central loop closure by satisfaction of spatial constraints, and (iii) refinement of the backbone and side-chain atoms of the ligand and receptor contact regions.

### Empirical free energy function

The scoring function presented herein is based on the free energy potential in ICM \[[@B23]\]. Computation of the binding free energy was performed according to previous similar work based on the difference between the energy of the solvated complex and the sum of the energy of the solvated receptor and that of the peptide ligand, followed by optimization using experimental IC~50~values \[[@B15]\]. This step was followed by 6-fold cross-validation for assessment of quality of the scoring function \[[@B15]\]. In *k*-fold cross-validation, *k*random, (approximately) equal-sized, disjoint partitions of the sample data were constructed, and all given models were trained on (*k*-1) partitions and tested on the excluded partition. The results were averaged after *k*such experiments, and thus the observed error rate may be taken as an estimate of the error rate expected upon generalization to new data. The predictive power of the models was assessed by the cross-validation coefficient *q*^2^and the standard error of prediction *s*~*press*~.

### Immunological hot spot prediction

In this study, \'immunological hot spots\' are defined as antigenic regions of up to 30 amino acids and modeled according to previous similar work based on the sum of predicted binding energies of the top four binders within a window of 30 amino acids \[[@B27]\]. Where available, these predicted hotspots were validated with available experimentally determined sites.

Training, testing and validation
--------------------------------

The free energy scoring function was calibrated using 6 peptides with experimental IC~50~values and tested on a dataset 58 peptides (54 binders and 4 non-binders) obtained from biochemical studies (Table [1](#T1){ref-type="table"}). The predictive performance of our model was assessed using sensitivity (SE), specificity (SP) and receiver operating characteristic (ROC) analysis \[[@B28]\]. SE = TP/(TP+FN) and SP = TN/(TN+FP), indicate percentages of correctly predicted binders and non-binders, respectively. TP (true positives) represents correctly predicted experimental binders and TN (true negatives) for experimental non-binders incorrectly predicted as binders. FN (false negatives) denotes experimental binders predicted as non-binders and FP (false positives) stands for experimental non-binders predicted as binders. The accuracy of our predictions was assessed by the ROC analysis where the ROC curve is generated by plotting SE as a function of (1-SP) for a complete range of classification thresholds. The area under the ROC curve (A~ROC~) provides a measure of overall prediction accuracy, A~ROC~\< 70% for poor, A~ROC~\> 80% for good and A~ROC~\> 90% for excellent predictions \[[@B15]\].

Abbreviations
=============

CTL, cytotoxic T lymphocyte; HLA, human leukocyte antigen; MHC, major histocompatibility complex; ER, endoplasmic reticulum; HIV, human immunodeficiency virus; ROC, receiver operating characteristic; SE, sensitivity; SP, specificity; TN, true negative; TP, true positive; FN, false negative; FP, false positive

Authors\' contributions
=======================

JCT carried out the computational modeling studies, participated in data analysis and drafted the manuscript. ZHZ helped in data collection and computational modeling studies. JTA, TWT, VB participated in experimental design. SR conceived the study, and participated in its design and coordination and finalized the manuscript. All authors read and approved the final manuscript.

Acknowledgements
================

This work was partly funded by the National Institute of Allergy and Infectious Diseases, National Institute of Health, USA (Grant \#5 U19 AI56541 & Contract \#HHSN266200400085C).
